Bifidobacterium is a genus—a group of related bacterial species—found in the human gut. These organisms participate in carbohydrate metabolism. A low stool result describes the assay’s measurement of a group, not a diagnosis of a deficiency that must be corrected with a particular supplement.
On this page
Why Bifidobacterium is studied
Different bifidobacteria use different carbohydrates and interact with other members of the intestinal community. Their metabolic products include acetate and lactate. These biological roles help explain scientific interest, but a total genus count does not measure every species’ function or your production of individual metabolites. [1]
What “low” means on GI-MAP
The result is below the laboratory’s comparison range for its targeted assay. It is not a census of every organism throughout the digestive tract, and below detection is not the same as proving the genus is absent from your body. Sample timing and recent diet, illness or antibiotic exposure belong in the interpretation. [2]
Read a reference with only a lower bound
The laboratory’s sample report lists Bifidobacterium spp. at 3.85e10 (38.5 billion genome equivalents per gram), with a reference of greater than 6.7e7 (67 million per gram). These are DNA-based quantities, not live culture counts. The “>” gives a lower bound. The nearby Lactobacillus row has both a lower and an upper bound. Compare each value with its own row. The sample’s Bifidobacterium result exceeds its lower bound; that does not turn the number into a treatment goal or show that a supplement is working. [4]
For the rest of the report, follow the GI-MAP sample report walkthrough.
Why a stool count cannot choose a probiotic
A probiotic label may name a species and a particular strain. Those details are more specific than a Bifidobacterium genus result. Evidence for one strain or indication cannot automatically be transferred to another product. [5] Increasing a report number is also not the same as demonstrating a health benefit.
The broader evidence for directing individual care from microbiome-composition results remains limited. Discuss your actual symptoms and goals before making a supplement decision from a low flag. [3]
Common questions
Does “spp.” identify the strain in my probiotic?
No. “Spp.” indicates a group of species. The genus row does not identify a product’s named strain or demonstrate that it has colonized your gut. Keep the full product label, including any strain designation, for a discussion about supplement evidence. [5]
Does low Bifidobacterium explain all my digestive symptoms?
No. The finding is not specific to one condition and cannot establish causation.
Can I compare this with a percentage on another microbiome test?
Not directly. A percentage, a DNA quantity and different laboratory target sets use different measurement systems. Compare like methods and units.
Questions to bring to your clinician
- Which symptoms or clinical findings need attention beyond this low flag?
- Does my report show a measured low value or “<dl” (below detection)?
- What symptom or health outcome would show whether a proposed intervention helps, beyond changing this number?
Sources and review
Sources checked November 17, 2026. Manufacturer material describes the test; clinical guidance and research support the interpretation limits.
- Bifidobacteria and their role in the human gut microbiota, 2016
- Diagnostic Solutions Laboratory: GI-MAP interpretive guide (manufacturer specifications)
- International consensus statement on microbiome testing in clinical practice (2025)
- Diagnostic Solutions Laboratory: GI-MAP sample report, page 2 (checked November 17, 2026)
- World Gastroenterology Organisation: Probiotics and prebiotics guideline (2023), strain-specific evidence
This article has been reviewed by Madison Ordway, FDN-P. For a correction or source question, contact Gi Map Test.